Publication | Closed Access

Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study

Lymphoid NeoplasiaChronic Lymphocytic LeukaemiaMedicineImmunologyImmune RegulationPathologyImmune SurveillanceImmune Checkpoint InhibitorImmunotherapeuticsImmunotherapyOncologyPhase 1